Nchi: Afrika Kusini
Lugha: Kiingereza
Chanzo: South African Health Products Regulatory Authority (SAHPRA)
Aspen-p
AP METHYLPRED (powder for injection) SCHEDULING STATUS: S4 PROPRIETARY NAME (and dosage form): AP METHYLPRED (powder for injection) Each 8 mL (when reconstituted) contains Methylprednisolone Sodium Succinate 662.5 mg equivalent to 500 mg Methylprednisolone . PHARMACOLOGICAL CLASSIFICATION: A 21.5.1 Corticosteroids and analogues PHARMACOLOGICAL ACTION: Pharmacodynamics: Methylprednisolone is a corticosteroid with mainly glucocorticoid activity. Corticosteroids have multiple mechanisms of action including anti-inflammatory activity, immunosuppressive properties, and antiproliferative actions. They have broad anti-inflammatory effects on cellular immunity resulting from decreased formation, release and activity of the mediators of inflammation (e.g. kinins, histamine, liposomal enzymes, prostaglandins, leukotrienes). Methylprednisolone has a potent anti-inflammatory action. The relative potency of methylprednisolone sodium succinate and hydrocortisone sodium succinate is at least four to one. Pharmacokinetics: Methylprednisolone is highly protein bound and is metabolised primarily by the liver, and to a lesser extent by the kidney. It is excreted in the urine. The elimination half-life ranges from 3,5 hours in normal healthy adults and is independent of the route of administration. INDICATIONS: AP METHYLPRED is indicated for conditions that require a rapid, potent corticosteroid effect, such as: • Allergic disorders, the severity of which necessitates the use of intravenous (IV) therapy, such as bronchial asthma, angioedema or anaphylaxis. • Collagen disorders, for the treatment of exacerbations thereof. This includes conditions such as systemic lupus erythematosis, polyarteritis nodosa, and systemic dermatomyositis. • Dermatological disorders which respond to steroids and are severe. • Endocrine disorders, Soma hati kamili